Monte Rosa Therapeutics Announced Interim Data From The Phase 1 Dose Escalation Part Of Its Ongoing Phase 1/2 Study Of MRT-2359 In Patients With MYC-driven Solid Tumors
Portfolio Pulse from Benzinga Newsdesk
Monte Rosa Therapeutics has announced interim data from the Phase 1 dose escalation part of its ongoing Phase 1/2 study of MRT-2359 in patients with MYC-driven solid tumors.

October 17, 2023 | 11:48 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Monte Rosa Therapeutics, which is mentioned in the context of its ongoing study of MRT-2359, may impact GLUE as it is related.
The news about Monte Rosa Therapeutics' ongoing study of MRT-2359 could potentially impact GLUE. However, the exact nature of this impact is not clear from the news article.
CONFIDENCE 70
IMPORTANCE 50
RELEVANCE 50